GWS
ACAD icon

Glassman Wealth Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Glassman Wealth Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55
Closed -$1.72K – 217
2023
Q4 		$1.72K Hold
55
– – ﹤0.01% 1392
2023
Q3 		$1.15K Hold
55
– – ﹤0.01% 1512
2023
Q2 		$1.32K Hold
55
– – ﹤0.01% 1367
2023
Q1 		$1.03K Hold
55
– – ﹤0.01% 1420
2022
Q4 		$876 Sell
55
-25
-31% -$391 ﹤0.01% 1459
2022
Q3 		$1K Sell
80
-6
-7% -$97 ﹤0.01% 1303
2022
Q2 		$1K Sell
86
-135
-61% -$2.52K ﹤0.01% 1324
2022
Q1 		$5K Buy
221
+28
+15% +$678 ﹤0.01% 983
2021
Q4 		$5K Buy
193
+92
+91% +$1.85K ﹤0.01% 961
2021
Q3 		$2K Buy
101
+35
+53% +$675 ﹤0.01% 1124
2021
Q2 		$2K Sell
66
-258
-80% -$5.82K ﹤0.01% 1101
2021
Q1 		$8K Buy
324
+62
+24% +$2.73K ﹤0.01% 755
2020
Q4 		$14K Buy
262
+197
+303% +$9.78K ﹤0.01% 618
2020
Q3 		$3K Hold
65
– – ﹤0.01% 873
2020
Q2 		$3K Hold
65
– – ﹤0.01% 718
2020
Q1 		$3K Buy
65
+6
+10% +$247 ﹤0.01% 583
2019
Q4 		$3K Buy
59
+4
+7% +$174 ﹤0.01% 648
2019
Q3 		$2K Sell
55
-8
-13% -$243 ﹤0.01% 660
2019
Q2 		$2K Sell
63
-14,992
-100% -$383K ﹤0.01% 684
2019
Q1 		$404K Buy
15,055
+55
+0.4% +$1.28K 0.18% 69
2018
Q4 		$243K Hold
15,000
– – 0.13% 87
2018
Q3 		$311K Hold
15,000
– – 0.14% 81
2018
Q2 		$229K Buy
15,000
+14,989
+136,264% +$267K 0.11% 82
2018
Q1 		$0 Buy
+11
New +$305 ﹤0.01% 717
2017
Q4 		– Sell
-140
Closed -$5K – 650
2017
Q3 		$5K Hold
140
– – ﹤0.01% 348
2017
Q2 		$4K Hold
140
– – ﹤0.01% 363
2017
Q1 		$5K Hold
140
– – ﹤0.01% 397
2016
Q4 		$4K Hold
140
– – ﹤0.01% 440
2016
Q3 		$4K Buy
+140
New +$4.75K ﹤0.01% 370

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Glassman Wealth Services's ACAD Position: Q1 2024 in Review

Glassman Wealth Services sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 55 shares — an estimated $1.72K sold.

Glassman Wealth Services first reported a position in ACAD in Q3 2016 and held it in 29 quarters. The position peaked at $404K in Q1 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Glassman Wealth Services reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 55 Acadia Pharmaceuticals shares in Q1 2024, an estimated $1.72K.
  • Glassman Wealth Services first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 29 quarters.
  • Glassman Wealth Services's Acadia Pharmaceuticals position peaked at $404K in Q1 2019.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.